Clinical Trial Update: Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating a modified DCF regimen (docetaxel, cisplatin, and fluorouracil) in unresectable or metastatic gastric and gastroesophageal junction a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Modified docetaxel, cisplatin, and fluorouracil (mDCF)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Gastroesophageal Junction Adenocarcinoma, Gastric Cancer | Phase 2 | Status: COMPLETED | Results posted: 2019-12-10